Marshall Wace’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Marshall Wace’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-453,992	Closed	-$4.59M	–	3473
2022 Q4	$4.59M	Hold	453,992	–	–	0.01%	1239
2022 Q3	$4.5M	Buy	453,992 +16,901	+4%	+$167K	0.01%	1441
2022 Q2	$4.27M	Hold	437,091	–	–	0.01%	1457
2022 Q1	$4.26M	Buy	437,091 +23,378	+6%	+$227K	0.01%	1487
2021 Q4	$4.01M	Buy	413,713 +87,961	+27%	+$856K	0.01%	1533
2021 Q3	$3.15M	Hold	325,752	–	–	0.01%	1228
2021 Q2	$3.15M	Buy	+325,752	New	+$3.2M	0.01%	1116

Marshall Wace's EBAC Position: Q1 2023 in Review

Marshall Wace sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 453,992 shares — an estimated $4.59M sold.

Marshall Wace first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $4.59M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Marshall Wace reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Marshall Wace sold 453,992 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $4.59M.
Marshall Wace first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Marshall Wace's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $4.59M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.